Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Evotec SE

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of companies like Axsome Therapeutics, Inc. and Evotec SE is crucial. Over the past decade, both companies have shown significant growth in their Selling, General, and Administrative (SG&A) expenses, reflecting their strategic investments in operations and market expansion.

From 2014 to 2023, Axsome Therapeutics, Inc. saw a staggering increase in SG&A expenses, growing by over 23,000% from 1.4 million to 323 million. This rapid escalation underscores their aggressive push in research and development, as well as market penetration. In contrast, Evotec SE's SG&A expenses grew by approximately 843%, reaching 170 million in 2023. This steady growth highlights their balanced approach to scaling operations while maintaining financial prudence.

These trends offer a window into the strategic priorities of each company, with Axsome focusing on rapid expansion and Evotec on sustainable growth.